Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

European Research Council grant · Running

StemAAV Targeted Genetic Manipulation of Muscle Stem Cells in vivo Towards New Treatment Strategies Against Muscular Dystrophies

Coordinator
Institut Pasteur, France
Runs
1 December 2026 to 31 May 2028
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101335140

What the project is doing

In the project's own words, from its summary on CORDIS.

Duchenne Muscular Dystrophy (DMD) is a devastating disorder affecting 1/5000 male births, leading to progressive muscle wasting and early mortality. Current gene therapy strategies for muscular dystrophies have shown partial benefits but remain limited by systemic toxicity, inefficient transduction of muscle stem cells (MuSCs), and a continuous turnover of muscle fibres that progressively reduces the therapeutic effect over time.

To address these bottlenecks, we propose a receptor-targeted gene delivery platform based on adeno-associated viruses (AAVs) engineered to selectively transduce MuSCs. Restoring Dystrophin expression in this rare but regenerative cell population may allow durable, stem cell-driven correction of muscle fibres in DMD.Building on strong preliminary findings, we have identified candidate MuSC-enriched cell-surface markers and will generate high-affinity ligands (DARPins) against these targets.

DARPins will be incorporated into AAV capsids blinded to their natural receptors, creating “DART-AAVs” targeting MuSCs through defined receptors while reducing transduction of non-target cells. DART-AAVs will be combined with CRISPR/Cas9 genome editing tools to restore Dystrophin expression in DMD mouse models. This PoC will deliver first-generation MuSC-targeted DART-AAV vectors for in vivo validation. We will also refine a translational strategy including IP protection, market analysis, and engagement with industrial and clinical stakeholders.

By focusing on MuSC targeting, this approach aims to reduce off-target toxicities, lower required viral loads, and exploit the intrinsic regenerative capacity of stem cells to sustain long-term muscle repair. We aim to deliver a MuSC-targeted gene delivery platform with strong clinical and commercial potential, for DMD and related muscle diseases. If successful, our PoC will pave the way for novel cell-type-focused gene therapies not only for DMD but also for other degenerative diseases.

Topics

Who is involved

OrganisationCityCountryRole
Institut PasteurParisFranceCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI